These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 10653272

  • 1. Pharmacology department: pharmacologic approaches to abnormal blood lipids.
    Gylys KH.
    J Cardiovasc Nurs; 2000 Jan; 14(2):9-15. PubMed ID: 10653272
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effects of gemfibrozil conversion to fenofibrate on lipids in patients on statin therapy.
    Corbelli JC, Bullano MF, Willey VJ, Cziraky MJ, Corbelli ME, Waugh W.
    Am J Cardiol; 2002 Dec 15; 90(12):1388-91. PubMed ID: 12480052
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. An ounce of prevention. Drugs used to treat hyperlipidemia (Part 1).
    Turkoski BB.
    Orthop Nurs; 2004 Dec 15; 23(1):58-61. PubMed ID: 14999954
    [Abstract] [Full Text] [Related]

  • 6. Choosing the right lipid-regulating agent. A guide to selection.
    Farmer JA, Gotto AM.
    Drugs; 1996 Nov 15; 52(5):649-61. PubMed ID: 9118815
    [Abstract] [Full Text] [Related]

  • 7. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW.
    Am J Cardiovasc Drugs; 2005 Nov 15; 5(6):379-87. PubMed ID: 16259526
    [Abstract] [Full Text] [Related]

  • 8. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
    Murdock DK, Murdock AK, Murdock RW, Olson KJ, Frane AM, Kersten ME, Joyce DM, Gantner SE.
    Am Heart J; 1999 Jul 15; 138(1 Pt 1):151-5. PubMed ID: 10385779
    [Abstract] [Full Text] [Related]

  • 9. Rationale for combination therapy with statin drugs in the treatment of dyslipidemia.
    Ansell BJ.
    Curr Atheroscler Rep; 2005 Feb 15; 7(1):29-33. PubMed ID: 15683599
    [Abstract] [Full Text] [Related]

  • 10. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
    Perreault S, Hamilton VH, Lavoie F, Grover S.
    Cardiovasc Drugs Ther; 1997 Jan 15; 10(6):787-94. PubMed ID: 9110123
    [Abstract] [Full Text] [Related]

  • 11. [Indications for the pharmacologic treatment of hyperlipidemias].
    Cía Gómez P.
    Rev Clin Esp; 2000 Nov 15; 200(11):622-5. PubMed ID: 11196593
    [No Abstract] [Full Text] [Related]

  • 12. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
    Keating GM, Ormrod D.
    Drugs; 2002 Nov 15; 62(13):1909-44. PubMed ID: 12215067
    [Abstract] [Full Text] [Related]

  • 13. Combination therapy for dyslipidemia: safety and regulatory considerations.
    Davidson MH.
    Am J Cardiol; 2002 Nov 20; 90(10B):50K-60K. PubMed ID: 12467940
    [Abstract] [Full Text] [Related]

  • 14. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks.
    Farnier M.
    Am J Cardiovasc Drugs; 2003 Nov 20; 3(3):169-78. PubMed ID: 14727929
    [Abstract] [Full Text] [Related]

  • 15. [Treatments for dyslipidemia associated with kidney disease].
    Hirano T, Yoshino G.
    Nihon Rinsho; 2001 Mar 20; 59 Suppl 3():748-52. PubMed ID: 11347167
    [No Abstract] [Full Text] [Related]

  • 16. Should we treat all primary prevention patients with statins?
    Guthrie R.
    Curr Atheroscler Rep; 2009 Jan 20; 11(1):36-42. PubMed ID: 19080726
    [Abstract] [Full Text] [Related]

  • 17. Drug treatment of lipid disorders.
    Knopp RH.
    N Engl J Med; 1999 Aug 12; 341(7):498-511. PubMed ID: 10441607
    [No Abstract] [Full Text] [Related]

  • 18. Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
    Schiel R, Bambauer R, Müller UA.
    Int J Artif Organs; 1995 Dec 12; 18(12):786-93. PubMed ID: 8964646
    [Abstract] [Full Text] [Related]

  • 19. Niacin as a component of combination therapy for dyslipidemia.
    Miller M.
    Mayo Clin Proc; 2003 Jun 12; 78(6):735-42. PubMed ID: 12934785
    [Abstract] [Full Text] [Related]

  • 20. Effects of fenofibrate and gemfibrozil on plasma homocysteine.
    Bostom AG.
    Lancet; 2001 Nov 24; 358(9295):1811-2. PubMed ID: 11734262
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.